Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5695685 | Gynecologic Oncology | 2017 | 6 Pages |
Abstract
While compliance of physicians with adjuvant therapy guidelines is excellent in patients with low and low-intermediate risk, there is room for improvement in high risk endometrial cancer patients. Eagerly awaited results of ongoing randomized clinical trials may provide more definitive guidance regarding adjuvant therapy for high risk endometrial cancer patients.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
F.A. Eggink, C.H. Mom, D. Boll, N.P.M. Ezendam, R.F.P.M. Kruitwagen, J.M.A. Pijnenborg, M.A. van der Aa, H.W. Nijman,